Literature DB >> 15667434

Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity?

R W Licht1, S Qvitzau, P Allerup, P Bech.   

Abstract

OBJECTIVE: Evaluation of antidepressant drug efficacy requires adequate rating scales for measuring the severity of depression. However, to measure the illness severity by such a total score, the scale needs to fulfil criteria of unidimensionality. On this background, we aimed at comparing the unidimensionality of the Bech-Rafaelsen Melancholia Scale (MES) and the 17-item Hamilton Depression Rating Scale (HAM-D(17)).
METHOD: A total of 1629 patients aged between 18 and 65 years with a major depressive episode were treated openly with sertraline at a fixed oral dose of 50 mg daily during 4 weeks. The HAM-D(17) and the MES were applied at baseline and at weeks 2 and 4. Unidimensionality was tested with Mokken and Rasch analysis.
RESULTS: Unidimensionality of the HAM-D(17) could not be confirmed. However, the 6-item Hamilton Depression Subscale (HAM-D(6)), was accepted by the Rasch analysis both at baseline and after 2 and 4 weeks of therapy. For the MES (as well as for the HAM-D(6)), a Loevinger coefficient of homogeneity above 0.40 (suggesting acceptance) was found at week 4.
CONCLUSION: The HAM-D(6) and the MES did fulfil criteria for unidimensionality while the HAM-D(17) did not. Therefore, the extended use of the HAM-D(17) in drug trials may be questioned.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667434     DOI: 10.1111/j.1600-0447.2004.00440.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  31 in total

1.  Depression rating scales in Parkinson's disease: critique and recommendations.

Authors:  Anette Schrag; Paolo Barone; Richard G Brown; Albert F G Leentjens; William M McDonald; Sergio Starkstein; Daniel Weintraub; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Christopher G Goetz
Journal:  Mov Disord       Date:  2007-06-15       Impact factor: 10.338

2.  The severity of psychiatric disorders.

Authors:  Mark Zimmerman; Theresa A Morgan; Kasey Stanton
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

3.  Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.

Authors:  Per Bech; Daniel K Kajdasz; Vibeke Porsdal
Journal:  Psychopharmacology (Berl)       Date:  2006-09-08       Impact factor: 4.530

4.  Measuring psychotic depression.

Authors:  S D Østergaard; B S Meyers; A J Flint; B H Mulsant; E M Whyte; C M Ulbricht; P Bech; A J Rothschild
Journal:  Acta Psychiatr Scand       Date:  2013-06-25       Impact factor: 6.392

5.  Clinical effectiveness of integrating depression care management into medicare home health: the Depression CAREPATH Randomized trial.

Authors:  Martha L Bruce; Patrick J Raue; Catherine F Reilly; Rebecca L Greenberg; Barnett S Meyers; Samprit Banerjee; Yolonda R Pickett; Thomas F Sheeran; Angela Ghesquiere; Diane M Zukowski; Vianca H Rosas; Jeanne McLaughlin; Lori Pledger; Joan Doyle; Pamela Joachim; Andrew C Leon
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

6.  Patient-Centered Research to Support the Development of the Symptoms of Major Depressive Disorder Scale (SMDDS): Initial Qualitative Research.

Authors:  Kelly P McCarrier; Linda S Deal; Lucy Abraham; Steven I Blum; Elizabeth Nicole Bush; Mona L Martin; Michael E Thase; Stephen Joel Coons
Journal:  Patient       Date:  2016-04       Impact factor: 3.883

7.  The DSM-IV definition of severity of major depression: inter-relationship and validity.

Authors:  V Lux; S H Aggen; K S Kendler
Journal:  Psychol Med       Date:  2010-01-08       Impact factor: 7.723

8.  Validation of the Rasch-based Depression Screening in a large scale German general population sample.

Authors:  Thomas Forkmann; Maren Boecker; Markus Wirtz; Heide Glaesmer; Elmar Brähler; Christine Norra; Siegfried Gauggel
Journal:  Health Qual Life Outcomes       Date:  2010-09-21       Impact factor: 3.186

9.  Validation of the 17-item Hamilton Depression Rating Scale definition of response for adults with major depressive disorder using equipercentile linking to Clinical Global Impression scale ratings: analysis of Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) data.

Authors:  William V Bobo; Gabriela C Angleró; Gregory Jenkins; Daniel K Hall-Flavin; Richard Weinshilboum; Joanna M Biernacka
Journal:  Hum Psychopharmacol       Date:  2016-03-21       Impact factor: 1.672

10.  Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method.

Authors:  Hans-Helmut König; Oliver H Günther; Matthias C Angermeyer; Christiane Roick
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.